Fingolimod (FTY720) HCl

For research use only.

Catalog No.S5002

88 publications

Fingolimod (FTY720) HCl Chemical Structure

CAS No. 162359-56-0

Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.

Selleck's Fingolimod (FTY720) HCl has been cited by 88 publications

Purity & Quality Control

Choose Selective S1P Receptor Inhibitors

Biological Activity

Description Fingolimod (FTY720) HCl is a S1P antagonist with IC50 of 0.033 nM in K562, and NK cells.
Targets
S1P receptor [1]
(K562, NK cells )
0.033 nM
In vitro

The inhibitory effect of S1P is revered by various concentrations of FTY720, with IC50 effect of 173 nM. In addition, FTY720 (10 nM) alone exerts no effect on the expression of co-stimulatory molecules. FTY720 reverses the increased expression of HLA-I induced by S1P for both the percentages of cells and the MFI, upon comparing the effect of S1P to the effect of combining S1P with FTY720. [1] Medium and high-dose FTY720-P also enhances the levels of TGF-β1. TGF-β1 and Foxp3 mRNA expression are upregulated in the high-dose FTY720-P group. The proliferation of effector T cells is suppressed significantly in the medium and high-dose FTY720-P group at a Treg/Teff cell ratio of 1:1. At a ratio of 1:1, the proliferation of effector T cells is also suppressed in the high-dose FTY720 group. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human U2OS cells MoDiSpVv[3Srb36gZZN{[Xl? MoPrRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXAyKHKnY3XweI9zKGW6cILld5Nm\CCrbjDoeY1idiCXMl;TJINmdGy|IHPvMYV5eHKnc4Ppcoch\UeIUDDhd5Nme3OnZDDhd{Bz\WOncITvdkBqdnSncn7hcIl7[XSrb36gbY51dyCleYTvdIxie21idYPpcochUG:nY3jzeEBlgWVic4ThbY5qdmduIFXDOVA:OC5yMEKg{txONg>? MnrYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMESxOFQoRjJ{MUC0NVQ1RC:jPh?=
human PC3 cells MWTDfZRwfG:6aXRCpIF{e2G7 NFO1V|Y4OiCq Mm\FR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTD2bZRidCCmeXWg[ZhkdHW|aX;uM4Ztd3diY4n0c41mfHKrYzDhcoFtgXOrczygTWM2OD17Lkig{txONg>? NFPOS4g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human NALM6 cells M{\FemN6fG:2b4jpZ:Kh[XO|YYm= MVO3NkBp Ml\IR5l1d3SxeHnjbZR6KGGpYXnud5QhWGhvbnXnZZRqfmViaIXtZY4hVkGOTU[gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVkvPiEQvF2u NHe2VpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human CCRF-CEM cells NVzZd4g1S3m2b4TvfIlkyqCjc4PhfS=> M{DSfVczKGh? NX7FOmY4S3m2b4TvfIlkcXS7IHHnZYlve3RiUHitcoVo[XSrdnWgbJVu[W5iQ1PSSk1ETU1iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJZqfGGuIHT5[UBmgGOudYPpc44w\myxdzDjfZRwdWW2cnnjJIFv[Wy7c3nzMEBKSzVyPU[uPEDPxE1w M3joVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
human SUP-B15 cells MmW3R5l1d3SxeHnjxsBie3OjeR?= NX\LNI1PPzJiaB?= M1XBT2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLYDvd4l1cX[nIHj1cYFvKFOXUD3CNVUh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTZwODFOwG0v NFrQd3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK3N|Y{Oid-MkSyO|M3OzJ:L3G+
human DU145 cells Mn3rR5l1d3SxeHnjxsBie3OjeR?= NVnRUm93PzJiaB?= NWj1TpFrS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KH[rdHHsJIR6\SCneHPseZNqd25xZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVYvPSEQvF2u MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ5M{[zNkc,OjR{N{O2N|I9N2F-
human BV173 cells NFX0fJNEgXSxdH;4bYPDqGG|c3H5 NX3VXndPPzJiaB?= M{HoXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KFCqLYDvd4l1cX[nIHj1cYFvKEKYMUezJINmdGy|IHHmeIVzKDd{IHjyd{BjgSC4aYThcEBlgWViZYjjcJV{cW:wL3\sc5ch[3m2b33leJJq[yCjbnHsfZNqeyxiSVO1NF03NjNizszNMi=> NYrmNFlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyO|M3OzJpPkK0Nlc{PjN{PD;hQi=>
human BLIN-1 cells NFXzSoZEgXSxdH;4bYPDqGG|c3H5 M2HOZVczKGh? NHrmVWlEgXSxdH;4bYNqfHliYXfhbY5{fCCSaD3u[YdifGm4ZTDoeY1idiCETFnOMVEh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7II\peIFtKGS7ZTDlfINtfXOrb36v[oxwfyCleYTvcYV1emmlIHHuZYx6e2m|LDDJR|UxRTVwNTFOwG0v M4XydFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
mouse bone marrow cells MmjGR5l1d3SxeHnjxsBie3OjeR?= NVHZT2FyPzJiaB?= NYnVZnJSS3m2b4TvfIlkcXS7IHHnZYlve3RiQlPSMWFDVCCodYPpc44heHKxdHXpckAyQTBiZYjwdoV{e2mwZzDtc5V{\SCkb37lJI1ienKxdzDj[YxteyCjZoTldkA4OiCqcoOgZpkhfmm2YXyg[JlmKGW6Y3z1d4lwdi:obH;3JIN6fG:vZYTybYMh[W6jbInzbZMtKEmFNUC9N{4{KM7:TT6= M3\zclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkezOlMzLz5{NEK3N|Y{OjxxYU6=
Sf9 insect cells NUnsSoNRTnWwY4Tpc44h[XO|YYm= MVOxJIg> M2TNeWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiU{HQUEApPjJidH:gOVY5MSCneIDy[ZN{\WRiaX6gV4Y6KGmwc3XjeEBk\WyuczD1d4lv\yCVMWCgZZMhe3Wkc4TyZZRmKGGodHXyJFEhcHJ? M3n2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEC5PFE1Lz5{NEiwPVgyPDxxYU6=
mouse MN9D cells MYDGeY5kfGmxbjDhd5NigQ>? NVi2N4NRPSEQvF2= MW\JcoR2[3Srb36gc4YhWFB{QTDjZZRidHm2aXOgd5VjfW6rdDDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbIF1\SCuZY\lcEBifCB3IIXN NVv5OYpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
rat PC12 cells MUfGeY5kfGmxbjDhd5NigQ>? NHzvcVY2KM7:TR?= NIj6XXc{OCC2bzCxNlAhdWmwcx?= MlWyTY5lfWO2aX;uJI9nKFCSMlGgZ4F1[Wy7dHnjJJN2[nWwaYSgZYN1cX[rdImgbY4hemG2IGDDNVIh[2WubIOgZZN{\XO|ZXSgZZMheGixc4DoZZRmKGyndnXsJIF1KDVidV2gcYVie3W{ZXSgN|AhfG9iMUKwJI1qdnNw MmXmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNUCxOlUoRjJ3MEWwNVY2RC:jPh?=
mouse MN9D cells Mly3SpVv[3Srb36gZZN{[Xl? MoDqNE4yPiEQvF2= NHXTNnAzPCCq M3:yNm5mfXKxcILveIVkfGm4ZTDhZ5Rqfmm2eTDpckBud3W|ZTDNUllFKGOnbHzzJIF{e2W|c3XkJIF{KHO2aX31cIF1cW:wIH;mJGJFVkZiZYjwdoV{e2mxbjDheEAxNjF4IIXNJIFnfGW{IEK0JIhzew>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB3MEG2OUc,OjVyNUCxOlU9N2F-
mouse MN9D cells M3LMbGZ2dmO2aX;uJIF{e2G7 NXewdYl{OC5zNjFOwG0> NH3RZZY4OiCq NX3De4ZFVmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIlvKG2xdYPlJG1PQURiY3XscJMh[XO|ZYPz[YQh[XNiYnzvZ4tqdmdib3[gWG5HNWGucHjhJIF{e2:laXH0[YQhfG:6aXPpeJkh[XRiMD6xOkB2VSCjZoTldkA4OiCqcoOgZpkhXHK7cHHuJIJtfWVic4ThbY5qdmdw NVmxfYYxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVAyPjVpPkK1NFUxOTZ3PD;hQi=>
CHO M3j5NGZ2dmO2aX;uJIF{e2G7 M3Hmc2Rqe3CuYXPlcYVvfCCxZjDbN|NRZXOyaHnu[49{cW6nIEGgdIhwe3CqYYTlJIZzd21iaIXtZY4hWzGSMTDy[YNmeHSxcjDlfJBz\XO|ZXSgbY4hS0iRIHPlcIx{NCCLQ{WwQVAvQDUQvF2u NEnhcJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNU[xOVUyOyd-MUW2NVU2OTN:L3G+
CHO M{mwb2Z2dmO2aX;uJIF{e2G7 NEG2b5JFcXOybHHj[Y1mdnRib3[gX|M{WF2|cHjpcodwe2mwZTCxJJBpd3OyaHH0[UBnem:vIHj1cYFvKFNzUEWgdoVk\XC2b4Kg[ZhxemW|c3XkJIlvKEOKTzDj[YxteyxiSVO1NF0zNjIQvF2u MonBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV4MUW1NVMoRjF3NkG1OVE{RC:jPh?=
Jurkat NXTudIVGTnWwY4Tpc44h[XO|YYm= M2HxN|E5KGi{cx?= Mk\3VoV3\XK|YXygc4YhcW6qaXLpeIlwdiCxZjDtbZRw[2ixbnTybYFtKG[3bnP0bY9vKGmwIHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiBzODDodpMhcW5icILld4Vv[2Vib3[gXk1XSURvZn3r NVfZd4U{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe0NFA2PTVpPkG3OFAxPTV3PD;hQi=>
T-cells NWnEbHY4TnWwY4Tpc44h[XO|YYm= MnnpPVYhcHK| M1jNRmludXWwb4P1dJBz\XO|aY\lJIFkfGm4aYT5JIlvKEKDTFKvZ{9EPTeETD:2JI1wfXOnIGSgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjbHzvZY51cWenbj3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDh[pRmeiB7NjDodpMh[nlibXXhd5VzcW6pIGuzTH11cHmvaXTpcoUhfXC2YXvlJIJ6KG2reHXkJIx6dXCqb3P5eIUhemWjY4Tpc44h[XO|YYmsJGlEPTB;MD6wNFYy|ryPLh?= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SK-BR-3 NHj2[pJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M2nnSFc5KGi{cx?= MnS4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCVSz3CVk0{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFc5KGi{czDifUBYW1RvMTDhd5NigSxiSVO1NF02|ryPLh?= NGrsd|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
MDA-MB-231 NV3xTXpKSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MkjPO|ghcHK| MUDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzhiaILzJIJ6KFeVVD2xJIF{e2G7LDDJR|UxRTYQvF2u NUm1Z|h4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
HCT116 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NX3WdZJCPzhiaILz NHPTR45CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6= MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR3NkWyOEc,OjF2NU[1NlQ9N2F-
SW620 NV73e444SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NV7SRnpXPzhiaILz NUjxVHFoSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW|YzOCClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6= NUL6UlZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0OVY2OjRpPkKxOFU3PTJ2PD;hQi=>
MCF7 NIDlc3VCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4W5N|c5KGi{cx?= MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{igbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUZOwG0v NHKzZVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUS1OlUzPCd-MkG0OVY2OjR:L3G+
LNCAP-AI MmHlRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NFvIbW84QCCqcoO= MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCOTlPBVE1CUSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4QCCqcoOgZpkhX1OWLUGgZZN{[XluIFnDOVA:Pc7:TT6= Mn3PQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2NU[1NlQoRjJzNEW2OVI1RC:jPh?=
MGC803 M3PxZ2FvfGm2dX3vdkBie3OjeR?= MknaNVAhdWdxa3e= NGHQe|YzOCCmYYnz Mn;RRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVfDPFA{KGOnbHzzJJhmdm:pcnHmeIVlKGmwIH71[IUhdW:3c3WgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjD0eY1weiCpcn;3eIgh[XRiMUCgcYcwc2diZn;yJFIxKGSjeYO= M4ixVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNEW2OVI1Lz5{MUS1OlUzPDxxYU6=
U2OS MonwSpVv[3Srb36gZZN{[Xl? MYixPEBpenN? MWLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGOxVFEhemWlZYD0c5Ih\XiycnXzd4VlKGmwIFXES|Eu[myjIGWyU3Mh[2WubIOgbY5kfWKjdHXkJIZweiBzODDodpMheHKrb4KgeI8hT2WwQnzhfoVzKHO3YoP0doF1\SCjZHTpeIlwdiCkeTDi[ZRiNWG{cnXzeIlvKHKnY4L1bZRu\W62IHHzd4F6NCCHQ{WwQVAvODB5Mt88UU4> MkW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4OEe0PFcoRjJ4Nki3OFg4RC:jPh?=
FL5.12A M1jXTWN6fG:2b4jpZ4l1gSCjc4PhfS=> MmXZOFghcHK| NYTxW3ZHS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhTkx3LkGyRUBk\WyuczDh[pRmeiB2ODDodpMh[nliRFHQTUB{fGGrbnnu[{1j[XOnZDDmcI94KGO7dH;t[ZRzcWNiYX7hcJl{cXNuIFnDOVA:Oi52zszNMi=> M{TIZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEe1OVM1Lz5{N{S3OVU{PDxxYU6=
SH-SY5Y NVnYT3J6S3m2b4TvfIlkcXS7IHHzd4F6 M{TKXVI1KGi{cx?= MmDhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2guW1l3WTDj[YxteyCvZXHzeZJm\CCjZoTldkAzPCCqcoOgZpkh[3K7c4ThcE13cW:uZYSgd5RicW6rbnegZoF{\WRiYYPzZZktKEWFMUC9NE42PM7:TT6= MlPxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
SK-N-SH MmrHR5l1d3SxeHnjbZR6KGG|c3H5 NE\0doozPCCqcoO= MWDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTT{1PNVOKIHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBkenm|dHHsMZZqd2yndDDzeIFqdmmwZzDiZZNm\CCjc4PhfUwhTUNzME2wMlU2|ryPLh?= NFqwTYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
U118MG M3nJSmN6fG:2b4jpZ4l1gSCjc4PhfS=> NF7LXpEzPCCqcoO= MnzNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVEyQE2JIHPlcIx{KG2nYYP1doVlKGGodHXyJFI1KGi{czDifUBkenm|dHHsMZZqd2yndDDzeIFqdmmwZzDiZZNm\CCjc4PhfUwhTUNzME2wMlYy|ryPLh?= MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzM{GxOUc,Ojd7MUOxNVU9N2F-
SH-SY5Y M4\UbWZ2dmO2aX;uJIF{e2G7 M{jVVmFod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbY4hcHWvYX6gV2guW1l3WTDj[YxteyCjc4Pld5Nm\CCjczDpcoNz\WG|ZTDpckBkSU2SIHzleoVtKGG2IFXDNVAh[nliZHny[YN1KGmvbYXuc4F{e2G7 MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd7MUOxNVUoRjJ5OUGzNVE2RC:jPh?=
U118MG NGLqTZdHfW6ldHnvckBie3OjeR?= NV3nU29WSWexbnnzeEBi[3Srdnn0fUBifCC|cHjpcodwe2mwZT2xMZBpd3OyaHH0[UBz\WOncITvdkBqdiCqdX3hckBWOTF6TVegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4h[0GPUDDs[ZZmdCCjdDDFR|ExKGK7IHTpdoVkfCCrbX31co9ie3OjeR?= NYD1PFlTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke5NVMyOTVpPkK3PVE{OTF3PD;hQi=>
SK-N-SH NXXJbYpnTnWwY4Tpc44h[XO|YYm= M4G0N2Fod26rc4SgZYN1cX[rdImgZZQhe3CqaX7nc5NqdmVvMT3wbI9{eGijdHWgdoVk\XC2b4KgbJVu[W5iU1utUk1UUCClZXzsd{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDjRW1RKGyndnXsJIF1KEWFMUCgZpkh\Gm{ZXP0JIludXWwb3Hzd4F6 NEjIXZI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
HEK293 Mn7QSpVv[3Srb36gZZN{[Xl? MmDSNVghcHK| NYPLXJc4SWexbnnzeEBi[3Srdnn0fUBifCC|cHjpcodwe2mwZT2xMZBpd3OyaHH0[UBz\WOncITvdkApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY1HNVEBt\X[nbDDheEBGSzFyIHHmeIVzKDF6IHjyd{BjgSCFUlWtdoV{eG:wc3n2[UBz\W6rbHzhJIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigQ>? NFvEc3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{mxN|EyPSd-Mke5NVMyOTV:L3G+
SJ-GBM2 Moe3dWhVWyCjc4PhfS=> NWC2c5NTeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> MlznQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
A673 NXSwcYpleUiWUzDhd5NigQ>? MlHKdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? M{PCSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MkjVdWhVWyCjc4PhfS=> NF2xWllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1OSyClZXzsdy=> NEGyfXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
BT-37 NIL4SHByUFSVIHHzd4F6 M13KRpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= MoDiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1 NWXGT4hUeUiWUzDhd5NigQ>? NE\neW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> M3;6bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2 MYHxTHRUKGG|c3H5 NUi0XmZ2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH M4\aNpFJXFNiYYPzZZk> MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= NFqxcVg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 Mne2dWhVWyCjc4PhfS=> NVPCTVE6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NF:4ZVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
LAN-5 NFrMN3lyUFSVIHHzd4F6 NGjndpVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NUfObm4zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 NGD4R5ByUFSVIHHzd4F6 NXTxcVhxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz NHS3cnE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 NUjmO|h3eUiWUzDhd5NigQ>? NVy4ZnQxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO= NF3OVXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MkDwdWhVWyCjc4PhfS=> NVXIRphReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> NH\EeYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
RD M1LUeJFJXFNiYYPzZZk> NIjqc4JyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN? M4i5cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MUDxTHRUKGG|c3H5 M3j4e5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?= NIPh[oM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh30 Mlm4dWhVWyCjc4PhfS=> MXHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh|MDDj[Yxtew>? MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 MWPxTHRUKGG|c3H5 MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>? MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
FL5.12 NH\BeYNEgXSxdH;4bYNqfHliYYPzZZk> MVO0PEBpenN? MnP6R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgSmw2NjF{IHPlcIx{KGGodHXyJFQ5KGi{czDifUBFSVCLIH;yJJBzd3CrZHn1cUBqd2SrZHWgd5RicW6rbnetZoF{\WRiZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{NCCLQ{WwQVIvOc7:TT6= MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7Mki5PEc,OzB{OUK4PVg9N2F-
FL5.12 MUXDfZRwfG:6aXPpeJkh[XO|YYm= NWTRNWU6OTBidV2= MknUN{BpenN? MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDGUFUvOTJiY3XscJMh[XO|ZYPz[YQh[XNidnHjeY9t\SCob4LtZZRqd25iYYSgNVAhfU1iYX\0[ZIhOyCqcoOgZpkh\my3b4Lld4NmdmOnIH3pZ5Jwe2OxcHnjJIFv[Wy7c3nz NFz1VGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK5Nlg6QCd-M{CyPVI5QTh:L3G+
FL5.12 MVzDfZRwfG:6aXPpeJkh[XO|YYm= NIPoeWQzNjVidV2= MWOzJIhzew>? NGfiUFBEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBHVDVwMUKgZ4VtdHNiYYPz[ZN{\WRiYYOgeoFkfW:uZTDmc5Ju[XSrb36gZZQhOi53IIXNJIFnfGW{IEOgbJJ{KGK7IH\seY9z\XOlZX7j[UBucWO{b4Pjc5Bq[yCjbnHsfZNqew>? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODJ7Mki5PEc,OzB{OUK4PVg9N2F-
HepG2 NEHMe5RyUFSVIHHzd4F6 MVLI[ZBIOiClZXzsd{B3cWGkaXzpeJkheUiWUzDmc5IhYmmtYTD2bZJ2eyCrbnjpZol1d3K| NHHHcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|M{KyPVU1PSd-M{OyNlk2PDV:L3G+
CHO Mmj0SpVv[3Srb36gZZN{[Xl? M{fUbWFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gV|FROyC{ZXPldJRweiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzJIF{e2W|c3XkJIF{KGmwY4LlZZNmKGmwIHPhcINqfW1iZnz1fEBjgSCjZYH1c5Jqdi2mZYLpeoVlKGy3bXnu[ZNk\W6lZTDhd5NigSxiRVO1NF0zNjVzMUi5{txONg>? MlzwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMN|E1QDV2Lze+R4hGVUKOPD;hQi=>
CHO M1HObGZ2dmO2aX;uJIF{e2G7 MkTYRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDTNXA2KHKnY3XweI9zKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO|ZXSgZZMhcW6lcnXhd4UhcW5iY3HsZ4l2dSCobIX4JIJ6KGGncYXvdolvNWSncnn2[YQhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwQVMvOTZ{MklOwG0v MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyzNVQ5PTRxJ{7DbGVOSkx:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cyclin D1 / CDK4 / cyclin E / CDK2 / p27 / p16 ; 

PubMed: 25344679     


FTY720 induces expression of p16 and p27 and reduces expression of cyclin D1, CDK4, cyclin E and CDK2. CC cells were treated with FTY720 at the indicated concentrations for 24 h. Lysates were then prepared immediately and analyzed by western blotting for cyclin D1, CDK4, cyclin E, CDK2, p16 and p27. β-Actin was used as the internal control. All assays were done in triplicate. 

p-STAT3 / STAT3 / Bcl-xl / Bcl-2 / Bax ; 

PubMed: 25344679     


CC cells were treated for 24 h with or without FTY720 and analyzed for the indicated protein by western blotting. 

p-AKT / AKT / p-mTOR / mTOR / p-GSK3β / GSK3β / p-IKKα/β / IKKα / NF-κB / Survivin; 

PubMed: 28717222     


Dose-dependent effects of FTY720 on the phosphorylation of Akt, mTOR, GSK3β, and IKKα/β, and the expression of NF-κB, and survivin in SCC2095 cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium for 24h, and cell lysates were immunoblotted as described in Material and Methods

25344679 28717222
Immunofluorescence
N-cadherin / Vimentin ; 

PubMed: 25344679     


Single and merged images show immunofluorescence staining of N-cadherin (green) and vimentin (red). The cell nucleus is stained blue by DAPI.

NF-κB; 

PubMed: 28717222     


Effect of FTY720 on the nuclear translocation of NF-κB. SCC2095 cells were treated with 5μM FTY720 for 24h, stained with anti-NF-κB, and examined by confocal microscopy.

25344679 28717222
Growth inhibition assay
Cell viability; 

PubMed: 28717222     


Effect of FTY720 at the indicated concentrations on the viability of oral cancer cells. Cells were treated with FTY720 in 5% FBS-supplemented DMEM/F12 medium in 96- well plates at 24h, and cell viability was assessed by MTT assays. Points, means; bars, S.D. (n=6). *P<0.01 compared to the control group.

28717222
In vivo FTY720 is effective in Ph+ but not Ph- ALL xenografts using an early disease model. FTY720 produces a significant reduction in disease burden in the Ph+ ALL xenografts using an early disease model. Ph+ human ALL xenografts responds to FTY720 with an 80 % reduction in overall disease if treatment has been initiated early on. In contrast, treatment of mice with FTY720 does not result in reduced leukemia compared to controls using four separate human Ph- ALL xenografts. [3]

Protocol

Cell Research:[1]
- Collapse
  • Cell lines: Immature DCs
  • Concentrations: 10 nM
  • Incubation Time: 4 hours
  • Method: Immature DCs are left intact or are incubated with 2 μM S1P, 10 nM FTY720, 10 nM SEW2871 or the combinations of S1P with these drugs for 4 hours. As a control 1 μg/mL LPS is used. The cells are washed and incubated in a 96-well plate (v-bottom, 2 × 105 cells per well), washed again and resuspended in PBS buffer containing 0.1% sodium azide. They are labeled with 1 μg/mL FITC-conjugated mouse anti-human CD80, 1 μg/mL FITC-conjugated mouse anti-human CD83, 1 μg/mL FITC-conjugated mouse anti-human CD86, 1 μg/mL FITC-conjugated mouse anti-human HLA-class I, 1 μg/mL FITC-conjugated mouse anti-human HLA-DR, 1 μg/mL FITC-conjugated mouse anti-human HLA-E, or 1 μg/mL FITC-conjugated mouse IgG as a control. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control FITC-conjugated mouse IgG. To stain NK cells with antibodies for various NK cell activating receptors, they are either left untreated or incubated with 2 μM S1P for 4 hours, washed and stained with 1 μg/mL PE-conjugated mouse anti-human NKp30 (CD337), 1 μg/mL PE-conjugated mouse anti-human NKp44 (CD336), 1 μg/mL PE-conjugated mouse anti-human NKG2D (CD314), or as a control 1 μg/mL PE-conjugated mouse IgG1, for 45 min at 4 °C. NK cells are also stained with 1 μg/mL FITC-conjugated anti-killer inhibitory receptor (KIR)/CD158 antibody which recognizes KIR2DL2, KIR2DL3, KIR2DS2 and KIR2DS4, and as a control with FITC-conjugated mouse IgG. The cells are washed twice, and examined in the flow cytometer. Markers are set according to the isotype control PE-conjugated or FITC-conjugated mouse IgG.
    (Only for Reference)
Animal Research:[3]
- Collapse
  • Animal Models: NOD/SCIDγc−/− mice bearing ALL cells.
  • Dosages: 5 mg/kg/day, 10 mg/kg/day
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (200.63 mM)
Water 69 mg/mL (200.63 mM)
Ethanol ''69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 343.9
Formula

C19H33NO2.HCl

CAS No. 162359-56-0
Storage powder
in solvent
Synonyms N/A
Smiles CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03345940 Terminated Drug: Fingolimod|Drug: Dimethyl Fumarate Relapsing Remitting Multiple Sclerosis Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta|Patient-Centered Outcomes Research Institute|Universita degli Studi di Genova April 30 2017 Phase 4
NCT02575365 Terminated Drug: 05 mg Fingolimod Cognition|Brain Volume Loss Novartis Pharmaceuticals|Novartis February 16 2016 Phase 4
NCT02490930 Completed Drug: Fingolimod Glioblastoma|Anaplastic Astrocytoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins July 2015 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

S1P Receptor Signaling Pathway Map

Related S1P Receptor Products

Tags: buy Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl supplier | purchase Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl cost | Fingolimod (FTY720) HCl manufacturer | order Fingolimod (FTY720) HCl | Fingolimod (FTY720) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID